Docs were shocked that lowering Lp(a) didn’t slash heart risks. Here’s what to know.

Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks ...

Shares of Novartis fell more than 3% on Monday after its cholesterol drug failed in a closely watched study, dealing ‌a blow ...

Most people need to take statins for a long time, and for some, the rest of their lives. According to experts, cholesterol ...

Researchers have designed a new DNA-based treatment that targets PCSK9, a protein closely tied to high LDL cholesterol and ...

The Phase 3 study found a drug didn’t reduce the risk of cardiovascular events like heart attacks and strokes.

Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This voice experience is generated by AI. Learn more. This ...

A new study has found that a cholesterol drug could lower heart attack risk in older adults. Here is how it can help and how ...

Mass General Brigham Heart and Vascular Institute researchers have found that high-risk patients who had not previously ...

LONDON, Sept 7 (Reuters) - Shares of Novartis fell 3.3% on Monday morning after its cholesterol drug failed in a closely ...

High cholesterol is one of the most common and manageable risk factors for heart disease. Millions of adults are prescribed cholesterol-lowering drugs to reduce low-density lipoprotein (LDL) ...

Add Yahoo as a preferred source to see more of our stories on Google. Over 140,000 bottles of a common cholesterol medication have been recalled because the pills "failed dissolution specifications," ...